Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study
- PMID: 27567054
- PMCID: PMC5052457
- DOI: 10.1016/S1470-2045(16)30275-3
Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study
Abstract
Background: Cervical cancer incidence remains high in several Baltic, central, and eastern European (BCEE) countries, mainly as a result of a historical absence of effective screening programmes. As a catalyst for action, we aimed to estimate the number of women who could be spared from cervical cancer across six countries in the region during the next 25 years, if effective screening interventions were introduced.
Methods: In this population-based study, we applied age-period-cohort models with spline functions within a Bayesian framework to incidence data from six BCEE countries (Estonia, Latvia, Lithuania, Belarus, Bulgaria, and Russia) to develop projections of the future number of new cases of cervical cancer from 2017 to 2040 based on two future scenarios: continued absence of screening (scenario A) versus the introduction of effective screening from 2017 onwards (scenario B). The timespan of available data varied from 16 years in Bulgaria to 40 years in Estonia. Projected rates up to 2040 were obtained in scenario A by extrapolating cohort-specific trends, a marker of changing risk of human papillomavirus (HPV) infection, assuming a continued absence of effective screening in future years. Scenario B added the effect of gradual introduction of screening in each country, under the assumption period effects would be equivalent to the decreasing trend by calendar year seen in Denmark (our comparator country) since the progressive regional introduction of screening from the late 1960s.
Findings: According to scenario A, projected incidence rates will continue to increase substantially in many BCEE countries. Very high age-standardised rates of cervical cancer are predicted in Lithuania, Latvia, Belarus, and Estonia (up to 88 cases per 100 000). According to scenario B, the beneficial effects of effective screening will increase progressively over time, leading to a 50-60% reduction of the projected incidence rates by around 2040, resulting in the prevention of cervical cancer in 1500 women in Estonia and more than 150 000 women in Russia. The immediate launch of effective screening programmes could prevent almost 180 000 new cervical cancer diagnoses in a 25-year period in the six BCEE countries studied.
Interpretation: Based on our findings, there is a clear need to begin cervical screening in these six countries as soon as possible to reduce the high and increasing incidence of cervical cancer over the next decades.
Funding: None.
Copyright © 2016 International Agency for Research on Cancer; licensee Elsevier. This is an Open Access article published under the CC BY NC-ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that IARC endorses any specific organisation, products or services. The use of the IARC logo is not permitted. This notice should be preserved along with the article's original URL.
Figures


Comment in
-
Improving cervical cancer screening in Baltic, central, and eastern European countries.Lancet Oncol. 2016 Oct;17(10):1349-1350. doi: 10.1016/S1470-2045(16)30388-6. Epub 2016 Aug 23. Lancet Oncol. 2016. PMID: 27567056 No abstract available.
Similar articles
-
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795950
-
Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.Lancet Public Health. 2018 Jan;3(1):e34-e43. doi: 10.1016/S2468-2667(17)30222-0. Epub 2017 Dec 19. Lancet Public Health. 2018. PMID: 29307386 Free PMC article.
-
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30. Lancet. 2020. PMID: 32007141 Free PMC article.
-
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029. Vaccine. 2013. PMID: 24332298 Review.
-
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.
Cited by
-
Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis.Int J Cancer. 2019 Feb 15;144(4):687-696. doi: 10.1002/ijc.31823. Epub 2018 Oct 16. Int J Cancer. 2019. PMID: 30132850 Free PMC article.
-
A preliminary cervical cancer screening cascade for eight provinces rural Chinese women: a descriptive analysis of cervical cancer screening cases in a 3-stage framework.Chin Med J (Engl). 2019 Aug 5;132(15):1773-1779. doi: 10.1097/CM9.0000000000000353. Chin Med J (Engl). 2019. PMID: 31335474 Free PMC article.
-
Recent advances in understanding and preventing human papillomavirus-related disease.F1000Res. 2017 Mar 14;6:F1000 Faculty Rev-269. doi: 10.12688/f1000research.9701.1. eCollection 2017. F1000Res. 2017. PMID: 28357043 Free PMC article. Review.
-
Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study.Lancet Oncol. 2021 Mar;22(3):361-369. doi: 10.1016/S1470-2045(20)30674-4. Epub 2021 Feb 5. Lancet Oncol. 2021. PMID: 33556324 Free PMC article.
-
Barriers and Facilitators to Cervical Screening among Migrant Women of African Origin: A Qualitative Study in Finland.Int J Environ Res Public Health. 2020 Oct 14;17(20):7473. doi: 10.3390/ijerph17207473. Int J Environ Res Public Health. 2020. PMID: 33066565 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
-
- Arbyn M, Antoine J, Magi M. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer. 2011;128:1899–1907. - PubMed
-
- Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262–3273. - PubMed
-
- Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013;31(suppl 7):H32–H45. - PubMed
-
- Poljak M, Seme K, Maver PJ. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013;31(suppl 7):H59–H70. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials